New approaches to the medical treatment of obesity

• Andrey F. Verbovoy

Abstract

Obesity is one of the most common chronic diseases requiring long-term combination therapy. This pathology is a risk factor for the development of diabetes, as well as cardiovascular diseases such as hypertension, coronary heart disease, chronic heart failure. Most often, Orlistat is used for the treatment of obesity, which is represented on the pharmaceutical market by various manufacturers. One of these drugs is the Listate (orlistat 120 mg). The article presents the data from the all-Russian observational non-interventional program for evaluating the efficacy and safety profile of using orlistat 120 mg for weight loss in patients with obesity in clinical practice. The results of the study, conducted with the participation of 1135 patients, showed a significant decrease not only in anthropometric indices, but also in systolic and diastolic blood pressure and heart rate. In the analysis of adverse events, 18 (1.6%) non-serious adverse drug reactions were identified. All of them arose from the gastrointestinal tract and were due to the pharmacological action of the drug, which prevents the absorption of fats from food. The frequency of adverse drug reactions that occur when taking orlistat 120 mg is lower than when using other drugs containing orlistat. Thus, it was shown that this drug has a significant positive effect on all indicators studied during the study, which are criteria for the effectiveness and safety of therapy.

Keywords:obesity, treatment, orlistat

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)